A systematic review of the effectiveness of adalimumab

More documents

Recommendations

Info

198 Appendix 10 Variation 8 For this variation, the effectiveness of conventional DMARDs was increased by 50% compared to the base case. TABLE 122 Variation 8: TNF inhibitors first (100,000 patients) Option Cost (£) QSE QALYs QSE Adal 49,674 102 10.2372 0.0182 Etan 63,645 123 10.3454 0.0188 Adal+MTX 49,702 103 9.4737 0.0170 Etan+MTX 64,356 125 9.7486 0.0178 Infl+MTX 49,177 98 9.3253 0.0171 Base 15,515 21 9.9405 0.0170 Comparison Diff. cost (£) QSE Diff. QALY QSE Adal – Base 34,160 100 0.2967 0.0188 Etan – Base 48,130 120 0.4048 0.0191 Ad+M – Base 34,187 101 –0.4668 0.0184 Et+M – Base 48,841 122 –0.1920 0.0187 In+M – Base 33,662 97 –0.6152 0.0184 Ad+M – Adal 27 139 –0.7635 0.0187 Et+M – Etan 711 165 –0.5968 0.0193 Etan – Adal 13,970 152 0.1082 0.0192 Et+M – Ad+M 14,654 154 0.2748 0.0186 Ad+M – In+M 525 136 0.1484 0.0181 Et+M – In+M 15,179 151 0.4232 0.0185 Comparison ICER (£ per QALY) Quasi-CI Adal – Base 115,000 102,000 to 132,000 Etan – Base 119,000 109,000 to 131,000 Ad+M – Base Base dominates Adal+MTX Et+M – Base Base dominates Etan+MTX In+M – Base Base dominates Infl+MTX Ad+M – Adal Adal alone more effective than Adal+MTX; diff. cost not significant Et+M – Etan Etan alone dominates Etan+MTX Etan – Adal 129,000 95,300 to 200,000 Et+M – Ad+M 53,300 46,900 to 61,800 Ad+M – In+M 3,530 1,500 to 5,560 Et+M – In+M 35,900 32,900 to 39,400 TABLE 123 Variation 8: TNF inhibitors third (early RA values) (100,000 patients) Option Cost (£) QSE QALYs QSE Adal 48,434 99 7.0553 0.0158 Etan 60,764 119 7.4295 0.0166 Adal+MTX 48,453 98 7.2055 0.0157 Etan+MTX 61,044 119 7.5540 0.0167 Infl+MTX 48,044 94 7.1746 0.0157 Base 16,612 23 6.4132 0.0145 Comparison Diff. cost (£) QSE Diff. QALY QSE Adal – Base 31,823 96 0.6420 0.0165 Etan – Base 44,152 115 1.0163 0.0170 Ad+M – Base 31,842 96 0.7922 0.0164 Et+M – Base 44,433 116 1.1407 0.0170 In+M – Base 31,432 92 0.7614 0.0164 Ad+M – Adal 19 131 0.1502 0.0168 Et+M – Etan 281 154 0.1245 0.0177 continued
TABLE 123 Variation 8: TNF inhibitors third (early RA values) (100,000 patients) (cont’d) © Queen’s Printer and Controller of HMSO 2006. All rights reserved. Health Technology Assessment 2006; Vol. 10: No. 42 Etan – Adal 12,329 143 0.3743 0.0173 Et+M – Ad+M 12,591 144 0.3485 0.0173 Ad+M – In+M 410 128 0.0309 0.0167 Et+M – In+M 13,001 141 0.3794 0.0173 Comparison ICER (£ per QALY) Quasi-CI Adal – Base 49,600 47,100 to 52,300 Etan – Base 43,400 42,000 to 45,000 Ad+M – Base 40,200 38,600 to 42,000 Et+M – Base 39,000 37,800 to 40,200 In+M – Base 41,300 39,600 to 43,200 Ad+M – Adal Adal+MTX more effective than Adal alone; diff. cost not significant Et+M – Etan Etan+MTX more effective than Etan alone; diff. cost not significant Etan – Adal 32,900 30,100 to 36,400 Et+M – Ad+M 36,100 32,800 to 40,200 Ad+M – In+M Adal+MTX more costly than Infl+MTX; diff QALY not significant Et+M – In+M 34,300 31,300 to 37,800 TABLE 124 Variation 8: TNF inhibitors third (late RA values) (200,000 patients) Option Cost (£) QSE QALYs QSE Adal 47,668 69 6.3544 0.0111 Etan 60,199 84 6.9127 0.0116 Adal+MTX 47,941 69 6.6445 0.0110 Etan+MTX 60,509 84 6.8989 0.0117 Infl+MTX 47,363 66 6.3784 0.0111 Base 16,657 16 6.4152 0.0103 Comparison Diff. cost (£) QSE Diff. QALY QSE Adal – Base 31,011 67 –0.0608 0.0113 Etan – Base 43,542 81 0.4975 0.0117 Ad+M – Base 31,284 67 0.2293 0.0114 Et+M – Base 43,852 82 0.4837 0.0119 In+M – Base 30,706 65 –0.0369 0.0114 Ad+M – Adal 273 91 0.2901 0.0113 Et+M – Etan 310 108 –0.0138 0.0121 Etan – Adal 12,531 100 0.5583 0.0117 Et+M – Ad+M 12,568 101 0.2544 0.0118 Ad+M – In+M 577 89 0.2661 0.0114 Et+M – In+M 13,145 98 0.5206 0.0118 Comparison ICER (£ per QALY) Quasi-CI Adal – Base Base dominates Adal Etan – Base 87,500 83,600 to 91,900 Ad+M – Base 136,000 124,000 to 151,000 Et+M – Base 90,700 86,400 to 95,300 In+M – Base Base dominates Infl+MTX Ad+M – Adal 941 310 to 1,570 Et+M – Etan Etan+MTX more costly than Etan; diff QALY not significant Etan – Adal 22,400 21,500 to 23,500 Et+M – Ad+M 49,400 45,200 to 54,500 Ad+M – In+M 2,170 1,470 to 2,870 Et+M – In+M 25,300 24,100 to 26,500 199
Page 1 and 2:
A systematic review of the effectiv
Page 3 and 4:
A systematic review of the effectiv
Page 5 and 6:
Objectives: This report reviews the
Page 7:
Glossary and list of abbreviations
Page 10 and 11:
viii Glossary and list of abbreviat
Page 13 and 14:
Background Rheumatoid arthritis (RA
Page 15:
increased risk of serious infection
Page 19 and 20:
Summary RA is a common, chronic, in
Page 21 and 22:
(IL-2) and interleukin-6 (IL-6), pr
Page 23 and 24:
Assessment of response to DMARDs Re
Page 25 and 26:
combination with methotrexate or al
Page 27:
disease between clinic appointments
Page 30 and 31:
14 Effectiveness in juvenile arthri
Page 32 and 33:
16 Effectiveness adalimumab plus me
Page 34 and 35:
18 Effectiveness Monoclonal Antibod
Page 36 and 37:
20 TABLE 1 Description of included
Page 38 and 39:
22 TABLE 2 Quality of included RCTs
Page 40 and 41:
24 Effectiveness change in modified
Page 42 and 43:
26 Effectiveness TABLE 4 Meta-analy
Page 44 and 45:
28 Effectiveness Review: Adalimumab
Page 46 and 47:
30 Effectiveness Review: Adalimumab
Page 48 and 49:
32 TABLE 6 Effectiveness Descriptio
Page 50 and 51:
34 TABLE 6 Effectiveness Descriptio
Page 52 and 53:
36 TABLE 7 Effectiveness Quality of
Page 54 and 55:
38 Effectiveness etanercept trials.
Page 56 and 57:
40 Effectiveness TABLE 9 Summary of
Page 58 and 59:
42 Effectiveness Review: Etanercept
Page 60 and 61:
Page 62 and 63:
Page 64 and 65:
Page 66 and 67:
Page 68 and 69:
Page 70 and 71:
54 Effectiveness TABLE 11 Summary o
Page 72 and 73:
56 TABLE 12 Description of included
Page 74 and 75:
58 TABLE 13 Quality of included RCT
Page 76 and 77:
60 Effectiveness per week and escal
Page 78 and 79:
62 Effectiveness significant advant
Page 80 and 81:
64 Effectiveness Review: Infliximab
Page 82 and 83:
66 Effectiveness Review: Infliximab
Page 84 and 85:
68 Effectiveness FIGURE 44 Malignan
Page 86 and 87:
70 TABLE 17 Effectiveness Summary o
Page 89 and 90:
Summary of review of existing econo
Page 91 and 92:
TABLE 20 Summary of published ICERs
Page 93 and 94:
TABLE 21 Published etanercept econo
Page 95 and 96:
TABLE 23 Published economic analyse
Page 97 and 98:
TABLE 25 Treatment sequences: adali
Page 99 and 100:
management of RA, i.e. 1st and 2nd
Page 101 and 102:
To estimate the long-term consequen
Page 103 and 104:
TABLE 32 TNF inhibitors as last act
Page 105 and 106:
TABLE 34 Basic structure of the mod
Page 107 and 108:
een quit on grounds of toxicity, ad
Page 109 and 110:
TABLE 39 Strategy set: adalimumab a
Page 111 and 112:
TABLE 43 Beta distributions for HAQ
Page 113 and 114:
TABLE 44 Early cessation of DMARDs:
Page 115 and 116:
TABLE 46 Unit costs for tests and v
Page 117 and 118:
following properties, according to
Page 119 and 120:
TABLE 52 Base case: TNF inhibitors
Page 121 and 122:
TABLE 54 Base case: TNF inhibitors
Page 123 and 124:
TABLE 59 Third TNF inhibitor follow
Page 125 and 126:
TABLE 65 Sensitivity analyses: TNF
Page 127 and 128:
TABLE 67 Sensitivity analyses: TNF
Page 129:
The substantial economic impact of
Page 133 and 134:
Summary Effectiveness: principal fi
Page 135 and 136:
inhibitors, although the incrementa
Page 137 and 138:
introduce bias which generally exag
Page 139:
Adalimumab, etanercept and inflixim
Page 143 and 144:
1. Jobanputra P, Barton P, Bryan S,
Page 145 and 146:
46. Young A, Dixey J, Cox N, Davies
Page 147 and 148:
tumor necrosis factor therapy in th
Page 149 and 150:
arthritis: a 12-week, double-blind,
Page 151 and 152:
171. Geborek P, Crnkic M, Petersson
Page 153 and 154:
216. Schotte H, Willeke P, Mickholz
Page 155 and 156:
The Health Assessment Questionnaire
Page 157 and 158:
Cochrane Library (CENTRAL) 2005 Iss
Page 159 and 160:
Appendix 3 © Queen’s Printer and
Page 161:
TABLE 69 Studies excluded from clin
Page 164 and 165: 148 Appendix 4 TABLE 71 Meta-analys
Page 166 and 167: 150 Appendix 4 TABLE 73 Meta-analys
Page 168 and 169: 152 Appendix 4 Infliximab versus pl
Page 170 and 171: 154 Appendix 4 Infliximab plus MTX
Page 173: Ovid MEDLINE(R) 1966 to February we
Page 177 and 178: Appendix 8 © Queen’s Printer and
Page 179 and 180: TABLE 79 Wong et al., 2002 161 © Q
Page 181 and 182: TABLE 80 Kobelt et al., 2003 162 (c
Page 183 and 184: TABLE 82 Brennan et al., 2004 160
Page 185 and 186: TABLE 83 Kobelt et al., 2004 163 (c
Page 187 and 188: TABLE 85 Bansback et al., 2005 166
Page 189: TABLE 86 Kobelt et al., 2005 167 (c
Page 192 and 193: 176 Appendix 9 TABLE 89 Strategy se
Page 195 and 196: Extensive sensitivity analysis was
Page 197 and 198: TABLE 96 Variation 1: TNF inhibitor
Page 199 and 200: TABLE 99 Variation 2: TNF inhibitor
Page 201 and 202: TABLE 102 Variation 3: TNF inhibito
Page 213: TABLE 120 Variation 7: TNF inhibito
Page 221 and 222: TABLE 132 Variation 10: TNF inhibit
Page 243: TABLE 165 Variation 18: TNF inhibit
Page 247 and 248: Volume 1, 1997 No. 1 Home parentera
Page 249 and 250: No. 3 Screening for sickle cell dis
Page 251 and 252: No. 25 A rapid and systematic revie
Page 253 and 254: No. 11 First and second trimester a
Page 255 and 256: No. 23 Clinical effectiveness and c
Page 257 and 258: No. 28 Outcomes of electrically sti
Page 259: No. 28 Adefovir dipivoxil and pegyl
Page 262 and 263: 246 Health Technology Assessment Pr
Page 264:
248 Health Technology Assessment Pr
show all

A systematic review of the effectiveness of adalimumab

Create successful ePaper yourself

Delete template?

Save as template?